All News
Filter News
Found 73,728 articles
-
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
3/20/2024
Achieve Life Sciences, Inc. today announced that three oral presentations featuring data from both of the Phase 3 ORCA-2 and ORCA-3 clinical trials of cytisinicline for smoking cessation and from the Phase 2 ORCA-V1 trial for e-cigarette cessation.
-
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
3/20/2024
AIM ImmunoTech Inc., announced the next CEO Corner segment has been published on the Company’s website.
-
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
3/20/2024
BioNTech SE announced that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
-
So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2023 Financial Results
3/20/2024
So-Young International Inc. announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023.
-
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
3/20/2024
Scilex Holding Company announced it will seek approval from the FDA for the modification of the Gloperba® label to include its ability to utilize dosing flexibility of liquid formulation to address unmet medical needs and provide specific dosing guidance to patients with renal impairment as set out below:
-
Pfizer Invites Public to View and Listen to Webcast of May 1, 2024 Conference Call with Analysts
3/20/2024
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, 2024.
-
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
3/20/2024
Immunic, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for patent application 16/981,122, entitled, "Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents," covering the composition-of-matter of a specific polymorph of vidofludimus calcium and a related method of production of the material.
-
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
3/20/2024
BioNTech SE reported financial results for the three months and full year ended December 31, 2023, and provided an update on its corporate progress.
-
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
3/20/2024
Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences.
-
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
3/20/2024
Valneva SE reported its consolidated financial results for the year ending December 31, 2023 and provided several key corporate updates.
-
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
3/20/2024
Moleculin Biotech, Inc. today announced that it will report its financial results for the year ended December 31, 2023, on Friday afternoon, March 22, 2024.
-
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS
3/20/2024
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2023.
-
Partnership agreement between Croda and AAHI to drive innovation in vaccine development
3/19/2024
Croda International Plc and The Access to Advanced Health Institute are pleased to announce the signing of a partnership agreement around innovation and development of adjuvant formulations, under which Croda and AAHI will leverage their combined expertise to make novel vaccine adjuvant formulations globally accessible, thereby advancing next generation, robust and durable vaccines.
-
Catheter Precision, Inc. (NYSE American:VTAK) to Sponsor the Monaco USA Arrhythmia Course
3/19/2024
Catheter Precision, Inc., a US based medical device company focused on electrophysiology products, is honored to be sponsor a session at the upcoming Monaco USA Arrhythmia Course taking place March 21-23 in Monaco.
-
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
3/19/2024
InflaRx N.V. announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential.
-
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
3/19/2024
Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.
-
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
3/19/2024
Coya Therapeutics, Inc. announces its financial results for the year ended December 31, 2023.
-
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
3/19/2024
Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® in the United Kingdom.
-
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
3/19/2024
Tonix Pharmaceuticals Holding Corp. today announced that it will achieve its goal of transitioning to a fully integrated pharmaceutical company on April 1, 2024.
-
International Harrington Prize Awarded to Dr. Arlene Sharpe
3/19/2024
The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.